Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 3,386 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Pathologies Clear all

Conditions: Breast Cancer, Lymphedema, Physical Therapy, Shoulder
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Chronic Conditions, Dementia
Interventions: Patient Priorities Care (PPC) Approach, Adapted PPC; Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 60 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 15 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma, Leukemia, Myeloma, Acute Lymphocytic Leukemia, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Recurrent Acute Myeloid Leukemia, Adult, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
Interventions: mycophenolate mofetil, Sargramostim, Filgrastim; Drug · Biological
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 74 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Lymphoid Leukemia
Interventions: Dasatinib, laboratory biomarker analysis; Drug · Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: SARS-CoV-2 Acute Respiratory Disease, Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, Post-acute Sequelae of SARS-COV-2 Infection, Post COVID-19 Condition
Interventions: Extension for Community Healthcare Outcomes; Other
Lead sponsor: Family Health Centers of San Diego; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Myocardial Infarction, Myocardial Ischemia
Interventions: thymosin beta 4, Placebo; Drug · Other
Lead sponsor: RegeneRx Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 79 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes type2, Obesity
Interventions: RESET Liner, Sham; Device · Other
Lead sponsor: Morphic Medical Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 27
States / cities: Gilbert, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 22 more

Conditions: Cancer of the Bile Duct
Interventions: Regorafenib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: Tampa, Florida • Chapel Hill, North Carolina • Richmond, Virginia

Conditions: Overweight , Obesity, Adults
Interventions: ALV-100, Placebo; Drug
Lead sponsor: Alveus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 16 more

Conditions: Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions: Asciminib single agent, Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib single agent pediatric formulation; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 7 Years to 100 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 6
States / cities: Ann Arbor, Michigan • New York, New York • Portland, Oregon + 3 more

Conditions: Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions: mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo; Drug
Lead sponsor: Astellas Pharma Europe Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 36
States / cities: Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more

Conditions: Chronic Pain
Interventions: Burst-capable SCS system, DRG Stimulator; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 21
States / cities: Camarillo, California • Carlsbad, California • La Jolla, California + 18 more

Conditions: Abdominal Obesity
Interventions: Experimental: eonTM FR 1064 nm device; Device
Lead sponsor: Dominion Aesthetic Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Altamonte Springs, Florida

Conditions: Acute Coronary Syndrome
Interventions: Not listed
Lead sponsor: Abbott RDx Cardiometabolic; Other
Eligibility: 19 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Boston, Massachusetts • Brooklyn, New York • Stony Brook, New York + 2 more

Conditions: Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Diseases, Non-Hodgkins Lymphoma, Hodgkins Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome
Interventions: Fludarabine monophosphate, Busulfan, Stem Cell Infusion, Tacrolimus, Methotrexate, G-CSF; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 5 Years to 75 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Proteinuria
Interventions: Belatacept; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2033
U.S. locations: 14
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia + 10 more

Conditions: Chronic Pain Syndrome
Interventions: MBSR treatment; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Obesity, Hypertension, Hyperlipidemia, Depression
Interventions: Self-care CVD risk reduction, Referral to primary care provider for CVD risk management; Behavioral · Other
Lead sponsor: Debra Moser; Other
Eligibility: 21 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Anxiety Disorder, Breast Cancer, Depression, Fatigue, Hot Flashes, Pain, Sleep Disorders
Interventions: acupuncture therapy, sham intervention; Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Major Depressive Disorder, Chronic Pain
Interventions: Active rTMS/Active iTBS DFPLC/Sham Pain M1, Active rTMS/Active iTBS; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Renal Disease, End Stage Renal Disease
Interventions: Droxidopa; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Acute Myocardial Infarction, STEMI
Interventions: FDY-5301, Placebo; Drug · Other
Lead sponsor: Faraday Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Minneapolis, Minnesota • The Bronx, New York

Search by objective public record fields.

Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer

Patient Priorities Care for Hispanics With Dementia

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?

A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

The RESET System Pivotal Clinical Trial (Protocol Revision K)

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

Asciminib Roll-over Study

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

PROLONG Prospective, Multi-center, Open-label, Post-market Study

Eon™ FR 1064 Full Abdomen Clinical Study Protocol

Multi-Markers In the Diagnosis of Acute Coronary Syndrome

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

Belatacept Conversion in Proteinuric Kidney Transplant Recipients

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Predictors of Pain Relief From Mindfulness-based Stress Reduction (MBSR) in Multiple Forms of Chronic Pain Patients

Improving Heart Health in Appalachia

Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer

Pain and Major Depressive Disorder

A Multi-Center, Open-Label Study

A Study of Acute Myocardial Infarction Using FDY-5301